TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04122768

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multi-component physical activity tele coaching intervention
Description: A.Education about the importance of PA. During a one-to-one interview with the coach motivation, self-efficacy, barriers, favorite activities and strategies to become more active are discussed.~B. Step counter providing direct feedback.~C.A smartphone with a project-tailored application. The application provides automated coaching by displaying an activity goal (number of steps) and feedback on a daily basis. The feedback comes with a graphical presentation. Patients' targets are automatically revised weekly. The aim is to progressively increase the PA during the 12 weeks period and maintain afterwards.~D.Telephone contacts triggered in the case of non-compliance with wearing the step counter, failure to transmit data or failure to progress. Coaches are alerted by a note at the coaches' backend to take contact with the patient if needed.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Light coaching intervention
Description: A. Education about the importance of PA. During a one-to-one interview with the investigator, patients will receive a personal goal (expressed in steps/day), based on their individual exercise capacity.~B.A step counter providing direct feedback.~C.A smartphone with a project-tailored application. The application receives the step data of the patient and asks on a weekly basis about the patient's change in medication. The application does provide a graph showing the steps the patient took and presents a general activity plan including their personal goal (which stays the same throughout the entire intervention period).
Study: NCT03262493

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Interventional Group
Description: Use of the feeding tube attachment device (FTAD).
Study: NCT00564707

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Biofeedback therapy
Description: EMG guided biofeedback therapy using standard biofeedback computer software

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Botulinum Toxin Type A Injection
Description: Under EMG guidance Botox is injected directly into the painful levator ani muscle.
Study: NCT02556645

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Web-PE Therapy
Description: Ten 60-minute psychotherapy sessions over 8 weeks, focused on gradually confronting distressing trauma-related memories and reminders. Web-PE is an internet-based version of prolonged exposure (PE) for posttraumatic stress disorder (PTSD).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Therapist-Delivered Present-Centered Therapy
Description: Ten 60-minute psychotherapy sessions over 8 weeks, focused on identifying and solving day-to-day problems as they are brought up by the participants. PCT is a manualized therapy that has been used as active control condition in several CBT studies. It provides a credible comparison therapy to control for nonspecific therapeutic factors so that observed effects of Web-PE can be attributed to its specific ingredients beyond the benefits of good therapy.
Study: NCT04576871

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 225Ac-J591
Description: In this study, subject enrollment will be done in a re-treatment design. A single dose of 225Ac-J591 given at the specified dose per cohort. The initial planned dose level will be determined based upon prior radioactivity exposure level. Those with moderate exposure (up to 30 GBq of 177Lu) will start with 65 KBq/Kg and those with heavy prior exposure (more than 30 Gbq of 177Lu or any 225Ac) will start with 50 KBq/Kg.
Study: NCT02885441

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketorolac
Description: Ketorolac, 10 mg, 3 times daily from time of enrollment until 72 hours from enrollment. For up to a maximum of 9 doses.
Study: NCT04626427

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: WavelinQ™ EndoAVF System
Description: AVF endovascular creations using the WavelinQ™ EndoAVF System
Study: NCT00858767

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: menaquinone-7 from casein capsules
Description: 90 µg menaquinone-7 daily during 8 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: menaquinone-7 from arabic gum capsules
Description: 90 µg menaquinone-7 daily during 8 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: menaquinone-7 from linseed oil capsules
Description: 90 µg menaquinone-7 daily during 8 weeks
Study: NCT01441687

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: transrectal prostate biopsy
Description: Undergo prostate biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: transrectal prostate biopsy
Description: Undergo prostate biopsy
Study: NCT00138125

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Faslodex
Description: Administered IM at 500 mg on day 1 of cycle 1, followed by 500 mg on day 15 of cycle 1, then 500 mg on day 1 of each cycle thereafter.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Herceptin
Description: Given at 4 mg/kg IV on day 1 (cycle 1) then 2mg/kg IV weekly
Study: NCT03243591

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Livionex gel
Description: Brushing area of mucositis with gel

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Aquafresh gel
Description: Aquafresh gel
Study: NCT00374907

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saxagliptin
Description: Tablet, Oral, 5 mg, Once daily, (up to 12 weeks ST, up to 104 weeks LT)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablet, Oral, 0 mg, Once daily (up to 12 weeks ST)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Metformin (blinded)
Description: Tablet, Oral, 500 mg titrated to 1000 mg, Once daily (up to 104 weeks LT, starting at Week 12)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Metformin (open-label)
Description: Tablets, Oral, 500-1500 mg, as needed (starting in LT)
Study: NCT04523285

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQB3728
Description: TQB3728 tablets is a small molecule oral drug.
Study: NCT01968044

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemigliptin

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo to Linagliptin
Study: NCT01140542

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Roflumilast
Description: 500µg, once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Roflumilast
Description: 500µg, once daily
Study: NCT04037358

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Radium-223
Description: Radium-223 plus SABR will be within two weeks.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: stereotactic ablative radiotherapy (SABR)
Description: SABR 1-5 fractions

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: stereotactic ablative radiotherapy (SABR)
Description: SABR 1-5 fractions
Study: NCT03103269

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Challenge! Small Group Intervention
Description: The Challenge! Small Group intervention consists of curriculum related to health behavior goal setting, healthy eating, and staying active, working out with Health Educators, and receiving a year-long membership to the YMCA.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Challenge! Small Group Intervention
Description: The Challenge! Small Group intervention consists of curriculum related to health behavior goal setting, healthy eating, and staying active, working out with Health Educators, and receiving a year-long membership to the YMCA.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Challenge! Environmental Intervention
Description: The environmental intervention involves the formation of a Health and Activity Committee composed of community members, teachers, parents, school staff, and 8th grade girls from the school. Together, this group comes up with ways to make their school environment healthier.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Challenge! Environmental Intervention
Description: The environmental intervention involves the formation of a Health and Activity Committee composed of community members, teachers, parents, school staff, and 8th grade girls from the school. Together, this group comes up with ways to make their school environment healthier.
Study: NCT03295097

Intervention type: OTHER
Group type: OTHER
Intervention: Clinical Decision Support System
Description: The system provides clinicians with patient-specific genetic information on opioid responsiveness and multi-drug interactions. This clinical decision support system should improve the clinician's ability to identify the optimal pain medication and dosage, and reduce risks associated with multi-drug treatment.
Study: NCT02003391

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Beta-blocker monotherapy
Description: Per participant's current prescribed therapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Travoprost 0.004% / timolol 0.5% fixed combination ophthalmic solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Travoprost 0.004% / timolol 0.5% fixed combination ophthalmic solution
Study: NCT03667963

Intervention type: OTHER
Group type: OTHER
Intervention: Glucose
Description: 50g glucose dissolved in 250ml water

Intervention type: OTHER
Group type: OTHER
Intervention: Glucose
Description: 50g glucose dissolved in 250ml water

Intervention type: OTHER
Group type: OTHER
Intervention: Glucose plus lactulose
Description: 50g glucose plus 10g lactulose dissolved in 250ml water

Intervention type: OTHER
Group type: OTHER
Intervention: Glucose plus lactulose
Description: 50g glucose plus 10g lactulose dissolved in 250ml water

Intervention type: OTHER
Group type: OTHER
Intervention: Hot Rice
Description: Freshly cooked polished rice containing 50g available carbohydrate (approximately 2/3 cup cooked rice) and consumed hot.

Intervention type: OTHER
Group type: OTHER
Intervention: Hot Rice
Description: Freshly cooked polished rice containing 50g available carbohydrate (approximately 2/3 cup cooked rice) and consumed hot.

Intervention type: OTHER
Group type: OTHER
Intervention: Cold Rice
Description: Cooked polished rice containing 50g available carbohydrate (approximately 2/3 cup cooked rice) cooled overnight in a refrigerator and consumed cold.

Intervention type: OTHER
Group type: OTHER
Intervention: Cold Rice
Description: Cooked polished rice containing 50g available carbohydrate (approximately 2/3 cup cooked rice) cooled overnight in a refrigerator and consumed cold.
Study: NCT02786433

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: conventional physiotherapy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual Reality with X- Box Kinect®
Study: NCT03224663

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Module based learning
Description: self-reading method using learner's guide module on FBNC provided by Department of Pediatrics.administered 45 minutes

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mobile application based learning
Description: learning method using android based mobile application on Facility Based Newborn Care provided by Division of Department of Pediatrics WHO-CC AIIMS FBNC deals with posters , videos , Modules.administered 45 minutes
Study: NCT02417428

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Citrulline
Description: Twelve weeks of citrulline oral supplementation will be taken by half of the participants (other are taken a placebo). Citrulline supplementation will be taken orally. Ten grams of citrulline (white powder) will be mixed with a liquid daily. Supplementation will be consumed once at lunch time.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Citrulline
Description: Twelve weeks of citrulline oral supplementation will be taken by half of the participants (other are taken a placebo). Citrulline supplementation will be taken orally. Ten grams of citrulline (white powder) will be mixed with a liquid daily. Supplementation will be consumed once at lunch time.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Twelve weeks of oral placebo will be taken by half of the participants. Ten grams of placebo (maltodextrin white powder) will be mixed with a liquid and will be consumed once daily at lunch time.
Study: NCT00802737

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ofatumumab
Description: Eight once weekly infusions (1 x 300 mg + 7 x 2000 mg), then 2000 mg once monthly for two years
Study: NCT01067495

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cardiac rehabilitation
Description: Participants will participate in a 6-month cardiac rehabilitation exercise program. This program will include aerobic and resistance training, and education sessions on risk factor management.
Study: NCT04531150

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INV-101
Description: Subjects will be randomized to receive INV-101 tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INV-101
Description: Subjects will be randomized to receive INV-101 tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INV-101
Description: Subjects will be randomized to receive INV-101 tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INV-101
Description: Subjects will be randomized to receive INV-101 tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INV-101
Description: Subjects will be randomized to receive INV-101 tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Subjects will be randomized to receive placebo tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Subjects will be randomized to receive placebo tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Subjects will be randomized to receive placebo tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Subjects will be randomized to receive placebo tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Subjects will be randomized to receive placebo tablets
Study: NCT02104856

Intervention type: DEVICE
Intervention: Alair System (Bronchial Thermoplasty)
Study: NCT04319003

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sugar-reduction intervention
Description: The intervention consisted of a) installation of a water filter at the school. b) each participant received a metal water bottle. c) a registered dietitian gave a 30-minute presentation on sugar reduction for the purposes of type 2 diabetes prevention
Study: NCT04238221

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxofylline
Description: Patients will receive a 4-week treatment with doxofylline 400 mg bid, in addition to their chronic usual inhalation therapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxofylline
Description: Patients will receive a 4-week treatment with doxofylline 400 mg bid, in addition to their chronic usual inhalation therapy.
Study: NCT04596527

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-FMPP
Description: 18F-FMPP were injected into the patients at rest (2.5 mCi) and during stress (6.0 mCi) for an individual subject before PET/CT scans.
Study: NCT01349829

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HAVpur Junior
Description: ≥12 International Units (IU) hepatitis A antigen coupled to virosomes, intramuscularly (i.m.), anterolateral thigh (M. vastus lateralis) or deltoid (M. deltoideus)~Vaccination schedule: single doses at 0 and 6 months

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Havrix 720 Junior
Description: ≥720 ELISA Units (EU) hepatitis A antigen adsorbed to aluminium hydroxide, intramuscularly (i.m.), anterolateral thigh (M. vastus lateralis) or deltoid (M. deltoideus)~Vaccination schedule: single doses at 0 and 6 months
Study: NCT02555371

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mepolizumab 100mg
Description: Mepolizumab is a fully humanised Immunoglobulin (IgG) antibody (IgG1, kappa) with human heavy and light chain frameworks. Mepolizumab will be provided as a lyophilised cake in sterile vials for individual use.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Mepolizumab 100mg
Description: Mepolizumab is a fully humanised Immunoglobulin (IgG) antibody (IgG1, kappa) with human heavy and light chain frameworks. Mepolizumab will be provided as a lyophilised cake in sterile vials for individual use.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo will be 0.9% sodium chloride solution and will be provided by the study site.
Study: NCT02992015

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Participants receive a one time IV dose of gemcitabine prior to having standard of care surgery.
Study: NCT00299689

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Denileukin diftitox
Description: 12 mcg/kg IV (in vein) over 30 minutes on days 1 through 4 of each 21 day cycle for 4 cycles.
Study: NCT03116763

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: iPeer2Peer Mentorship
Description: 10 sessions of 20-30 minute Skype calls conducted over 5-12 weeks.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Active Comparator: Control Group
Description: The control group will receive standard care but without the iPeer2Peer program.
Study: NCT02064621

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Candesartan 32mg
Description: Candesartan 32mg 1T, PO, QD for 9days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Candesartan 32mg/Amlodipine 10mg
Description: Candesartan 32mg 1T, PO, QD for 9days/Amlodipine 10mg 1T, PO, QD for 9days
Study: NCT04037111

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical vagus nerve stimulation
Description: The patient received active VNS and escitalopram oxalate tablets for 2 months.When the VNS was stimulated, the two electrodes were vertically attached to the left carotid sinus at 2cm, or the auricular clip electrode was applied to the tragus.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham vagus nerve stimulation
Description: The patient received sham VNS.When the VNS was stimulated, the two electrodes were vertically attached to the left carotid sinus at 2cm, or the auricular clip electrode was applied to the tragus.

Intervention type: DRUG
Group type: OTHER
Intervention: drug treatment
Description: Escitalopram oxalate tablets should be taken orally once every morning for 2 months, each time 10-20mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: drug treatment
Description: Escitalopram oxalate tablets should be taken orally once every morning for 2 months, each time 10-20mg

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: drug treatment
Description: Escitalopram oxalate tablets should be taken orally once every morning for 2 months, each time 10-20mg
Study: NCT02334319

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ganetespib
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Therapeutic Conventional Surgery
Description: Undergo surgery

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT01625910

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Behavioral counseling
Description: Counseling of parents to improve their child's diet and physical activity

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral counseling
Description: Counseling of parents to improve their child's diet and physical activity
Study: NCT02990221

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ingenol mebutate
Description: 150 mcg / g per day, to be applied on a predetermined area of 25 cm2 of skin of the face or scalp, for 3 days consecutive

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: cryotherapy
Description: application with 5 seconds of freezing time of each lesion located in a predetermined skin area of 25 cm2 of the face or scalp
Study: NCT03299374

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pilates Intervention
Description: Intervention based on Pilates principles

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fall prevention intervention
Description: Intervention based on principles to prevent falls
Study: NCT01096732

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GDC-0449
Description: Gelatine capsules of 150mg.Taken O.D. for 14 days.
Study: NCT00218985

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise training
Description: Intensity controlled exercise training before the scheduled bypass surgery
Study: NCT03638856

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Misoprostol 200Mcg Tab
Description: patient takes 2 tab of 200 mcg of Misoprostal 3 hr before hysteroscopy
Study: NCT00724334

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR302503 (TG101348)
Description: orally administered, once a day
Study: NCT02283099

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rVSVΔ-ZEBOV-GP
Description: single dose of rVSVΔ-ZEBOV-GP (3x10\^6 pfu, 2x10\^7 pfu or 3x10\^5)
Study: NCT03575442

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: 3 session program of art therapy
Description: With this program, we expect to offer socio-emotional well-being in the psychiatric context, and creative self-expression through painting. In addition, we hope to provide contributions towards the creation of quality standards of the professional practice of nurses, within the context of implementing psychosocial programs in mental health.
Study: NCT01907399

Intervention type: OTHER
Group type: OTHER
Intervention: Blood samples

Intervention type: OTHER
Group type: OTHER
Intervention: Blood samples

Intervention type: OTHER
Group type: OTHER
Intervention: Blood samples
Study: NCT04880915

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: surgical smoke affects
Description: The study, experimental type, was conducted to investigate the effects of five different methods on surgical smoke protection.
Study: NCT04129411

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RFA
Description: Radiofrequency ablation of selectively targeted thyroid nodule to treat papillary thyroid cancer.
Study: NCT03693820

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: the infiltration group
Description: * 15-20 ml periportal,~* 50 ml in gallbladder bed,~* The rest (about 150 ml in 70 Kg patient) will be intraperitoneal

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: the control group
Description: the 50 ml prepared for gallbladder bed infiltration will be replaced by saline.